today the registrationprocess and marketing of NGAL in Latin America was initiated, but unfortunately not by Alere, although Alere has spent millions of dollars in marketing this new emerging biomarker that will revolutionize the treatment of AKI (Acute Kidney Injury). Alere is promoting NGAL testing on their Triage POC system.
Why is this important to Alere you might ask ? Well - NGAL was the core product-line of Biosite - a company that Alere invested 1,6 billion dollars in.. please see Roy Zwanzigers remarks : http://medicoinvestor.com/presentations/ (slide 2)
AKI is an injury that kills more than 4 million people every year (in the western hemisphere alone) costing billions of dollars in prolonged hospitalisation. Alere have tried to obtain a license from danish micro-cap company Bioporto (biopor at nasdaqomx.dk) who holds a patent defining the threshold values defining when AKI is imminent. Alere is using the good cop - bad cop tactics - hitherto unsuccesfully a NGAL test - is a potential blockbuster - equivalent to the hearts troponin. Read more about this important invention - and the struggle between Alere and Bioporto at http://medicoinvestor.com/ - and learn why this is extraordinarily important- not only to Alere - but first and foremost to the 13 million patients annually affected by AKI..